PMGC Holdings Files S-1 for 5M Share Resale, Shifts Focus to Biotech

Ticker: ELAB · Form: S-1 · Filed: Oct 16, 2025 · CIK: 1840563

Sentiment: mixed

Topics: S-1 Filing, Biotechnology, Resale Offering, Equity Purchase Facility, Reverse Stock Split, Emerging Growth Company, Diversified Holdings, Obesity Treatment, Intellectual Property

Related Tickers: ELAB

TL;DR

**ELAB is dumping skincare for biotech and industrial plays, but this S-1 is just a resale, so don't expect a pop from new capital.**

AI Summary

PMGC Holdings Inc. (ELAB) is offering up to 5,000,000 shares of common stock for resale by certain selling security holders, including 56,700 commitment shares and 10,300 pre-delivery shares issued to Streeterville Capital, LLC, following a $5,000,000 initial pre-paid purchase on September 26, 2025. The company will not receive any proceeds from this resale offering, but can receive up to $20 million in aggregate from the equity purchase facility. PMGC Holdings Inc. recently divested its Elevai Skincare Inc. business on January 16, 2025, to focus on larger markets and biotechnology assets through Northstrive Biosciences Inc. and PMGC Research Inc. Northstrive Biosciences is advancing EL-22, an engineered probiotic for muscle preservation during weight loss, which completed a Phase 1 clinical trial in South Korea and plans an IND filing with the FDA. The company also operates PMGC Capital LLC for investments, Pacific Sun Packaging, Inc. for specialty packaging, and AGA Precision Systems LLC for CNC machining. A 1:3.5 reverse stock split was effected on September 2, 2025, and the common stock traded at $9.03 per share on October 14, 2025.

Why It Matters

This S-1 filing signals PMGC Holdings' strategic pivot away from skincare to a diversified portfolio heavily weighted towards biotechnology and industrial operations, potentially offering investors exposure to high-growth, yet high-risk, sectors. The divestiture of Elevai Skincare Inc. and the focus on EL-22, a probiotic targeting muscle preservation with GLP-1 agonists, positions ELAB in a competitive and rapidly evolving obesity treatment market. For employees, this shift could mean new opportunities in biotech and manufacturing, while customers of the divested skincare business will need to adjust. The equity purchase facility with Streeterville Capital, LLC, while providing potential capital, also introduces dilution risk for existing shareholders.

Risk Assessment

Risk Level: high — The company explicitly states, "Investing in our securities involves a high degree of risk." This is further evidenced by its status as an "emerging growth company" and "smaller reporting company," which are subject to reduced public company reporting requirements. The reliance on an equity purchase facility for up to $20 million, where the company will not receive proceeds from the current 5,000,000 share resale, indicates potential future dilution for investors.

Analyst Insight

Investors should carefully evaluate PMGC Holdings' new strategic direction, particularly the clinical development risks associated with Northstrive Biosciences' EL-22 and EL-32 assets. Given the high-risk profile and the fact that the company will not receive proceeds from this specific resale offering, potential investors should conduct thorough due diligence on the underlying business fundamentals and future capital needs before considering an investment.

Financial Highlights

debt To Equity
0.0
revenue
$0
operating Margin
0%
total Assets
$0
total Debt
$0
net Income
$0
eps
$0
gross Margin
0%
cash Position
$0
revenue Growth
+0%

Executive Compensation

NameTitleTotal Compensation
Not DisclosedChief Executive Officer$0
Not DisclosedChief Financial Officer$0
Not DisclosedChief Operating Officer$0

Key Numbers

Key Players & Entities

FAQ

What is PMGC Holdings Inc.'s primary business strategy after the S-1 filing?

PMGC Holdings Inc.'s primary business strategy is to acquire and grow valuable assets and operating businesses across various industries, with a renewed focus on biotechnology through Northstrive Biosciences Inc. and industrial operations, following the divestiture of Elevai Skincare Inc. on January 16, 2025.

How much capital can PMGC Holdings Inc. receive from the equity purchase facility?

PMGC Holdings Inc. can receive a maximum gross proceeds of $20 million in the aggregate from the equity purchase facility contemplated by the Purchase Agreement with Streeterville Capital, LLC. However, the company will not receive any proceeds from the current 5,000,000 share resale offering.

What is EL-22 and its development status for PMGC Holdings Inc.?

EL-22 is Northstrive Biosciences Inc.'s lead asset, an engineered probiotic designed to preserve muscle mass during weight loss treatments, including GLP-1 receptor agonists. It has completed a Phase 1 clinical trial in South Korea, showing promising safety and tolerability, and the company plans to file an Investigational New Drug (IND) application with the U.S. FDA.

What are the key risks associated with investing in PMGC Holdings Inc. (ELAB) securities?

Investing in PMGC Holdings Inc. securities involves a high degree of risk, as explicitly stated in the S-1 filing. Risks include those inherent in emerging growth companies, potential dilution from future equity issuances under the $20 million equity purchase facility, and the competitive and uncertain nature of the biopharmaceutical and other industries in which its subsidiaries operate.

When did PMGC Holdings Inc. effect its reverse stock split?

PMGC Holdings Inc. effected a 1:3.5 reverse stock split of its issued and outstanding shares of Common Stock on September 2, 2025.

What was the last reported sale price of PMGC Holdings Inc. (ELAB) Common Stock?

On October 14, 2025, the last reported sale price of PMGC Holdings Inc. Common Stock (ELAB) was $9.03 per share.

Who are the selling shareholders in this S-1 filing for PMGC Holdings Inc.?

The primary selling security holder identified in this prospectus is Streeterville Capital, LLC, a Utah limited company, which holds up to 5,000,000 shares of common stock for resale, including commitment shares and pre-delivery shares.

What intellectual property does PMGC Holdings Inc. possess related to its biotechnology assets?

As of October 15, 2025, PMGC Holdings Inc. has four non-provisional patent applications and four provisional patent applications filed, primarily related to fusion proteins of Myo-2 for treating muscle loss in obese patients and combination therapies with GLP-1 receptor agonists.

Why did PMGC Holdings Inc. divest Elevai Skincare Inc.?

PMGC Holdings Inc. divested Elevai Skincare Inc. on January 16, 2025, to dedicate more resources and time to advancing initiatives and assets in larger markets with unmet needs, creating greater growth opportunities, particularly in the clinical development of biotechnology assets through NorthStrive Biosciences Inc.

Is PMGC Holdings Inc. considered an 'emerging growth company'?

Yes, PMGC Holdings Inc. is an "emerging growth company" as defined in Section 2(a) of the Securities Act of 1933, as amended, and a "smaller reporting company," which means it is subject to reduced public company reporting requirements.

Risk Factors

Industry Context

PMGC Holdings Inc. is navigating the dynamic biotechnology and specialty manufacturing sectors. The biotechnology landscape is characterized by high R&D costs, lengthy development cycles, and stringent regulatory hurdles, with companies like Northstrive Biosciences aiming to disrupt areas like muscle preservation. The specialty packaging and CNC machining segments operate in more mature markets, requiring efficiency and customization to compete.

Regulatory Implications

The company faces significant regulatory scrutiny, particularly concerning its biotechnology assets. The planned IND filing for EL-22 necessitates adherence to FDA guidelines for clinical trials and drug approval. Furthermore, any future public offerings or capital raises will be subject to SEC regulations, and the company must maintain compliance with exchange listing requirements.

What Investors Should Do

  1. Monitor Northstrive Biosciences' progress on the IND filing for EL-22 and subsequent clinical trial results, as this is a key value driver.
  2. Evaluate the terms and conditions of the equity purchase facility with Streeterville Capital, LLC, understanding the potential for dilution and the company's ability to manage drawdowns.
  3. Assess the strategic rationale and execution risk associated with the divestiture of Elevai Skincare and the integration of new biotechnology assets.
  4. Analyze the market potential and competitive landscape for EL-22 and other pipeline assets once more data becomes available.
  5. Review the company's long-term funding strategy beyond the current equity purchase facility to ensure sustainable growth.

Key Dates

Glossary

Equity Purchase Facility
A financial arrangement where an investor commits to purchase shares of a company's stock over a period, up to a specified amount, often at the company's discretion. (This is the primary funding mechanism for PMGC Holdings Inc., allowing it to draw up to $20 million, but it involves the issuance of shares which can dilute existing shareholders.)
IND Filing
Investigational New Drug application, a submission to the FDA to seek permission to start clinical trials in humans for a new drug or biologic. (Northstrive Biosciences' plan to file an IND for EL-22 is a critical step towards potential FDA approval and commercialization of their lead product candidate.)
Reverse Stock Split
A corporate action where a company reduces the total number of its outstanding shares by consolidating existing shares into fewer, proportionally more valuable shares. (PMGC Holdings Inc. effected a 1:3.5 reverse stock split, which impacts the share count and potentially the stock price, often done to meet exchange listing requirements or attract institutional investors.)
Commitment Shares
Shares issued to an investor as part of a commitment agreement, often related to a financing facility, serving as an incentive or part of the overall transaction cost. (56,700 commitment shares were issued to Streeterville Capital, LLC, representing a cost of capital for the equity purchase facility.)
Pre-Delivery Shares
Shares provided to an investor in advance of the full execution of a purchase agreement, often as a gesture of good faith or to facilitate early stages of the transaction. (10,300 pre-delivery shares were issued to Streeterville Capital, LLC, alongside commitment shares, as part of the financing arrangement.)

Year-Over-Year Comparison

This S-1 filing represents a significant strategic pivot for PMGC Holdings Inc., marked by the divestiture of its skincare business and a renewed focus on biotechnology through Northstrive Biosciences. Unlike previous filings that might have reflected the skincare operations, this document emphasizes the potential of EL-22 and the company's reliance on a new equity purchase facility for funding. Key metrics such as revenue, profitability, and margins are not detailed in this filing, making a direct comparison of financial performance difficult. However, the introduction of new risks related to clinical trials and regulatory approvals is evident.

Filing Stats: 4,320 words · 17 min read · ~14 pages · Grade level 14.7 · Accepted 2025-10-15 19:28:22

Key Financial Figures

Filing Documents

RISK FACTORS

RISK FACTORS 19 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 27

USE OF PROCEEDS

USE OF PROCEEDS 28 MARKET PRICE OF OUR COMMON STOCK AND RELATED STOCKHOLDER MATTERS 28 PRIVATE PLACEMENT OF WARRANTS 29

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 32

BUSINESS

BUSINESS 55 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 80 MANAGEMENT 87

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 93 PRINCIPAL STOCKHOLDERS 109 SELLING SHAREHOLDERS 111

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 112 PLAN OF DISTRIBUTION 116 EXPERTS 117 LEGAL MATTERS 117 WHERE YOU CAN FIND MORE INFORMATION 117 INFORMATION INCORPORATED BY REFERENCE 118 INDEX TO FINANCIAL STATEMENTS F-1 You should rely only on the information contained in this prospectus or any prospectus supplement or amendment. We have not authorized any other person to provide you with information that is different from, or adds to, that contained in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. We do not take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. You should assume that the information contained in this prospectus or any free writing prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. We are not making an offer of any securities in any jurisdiction in which such offer is unlawful. No action is being taken in any jurisdiction outside the United States to permit a public offering of our securities or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this public offering and the distribution of this prospectus applicable to that jurisdiction. i ABOUT THIS PROSPECTUS Throughout this prospectus, unless otherwise designated or the context suggests otherwise, all references to the "Company," "PMGC," the "registrant," "we," "our" or "us" in this prospectus mean PMGC Holdings Inc. and its wholly owned subsidiaries, PMGC Capital LLC, Northstrive Biosciences Inc. PMGC Research Inc., Pacific Sun Packaging, Inc., and AGA Pre

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing